Keros Therapeutics, Inc. Common Stock (KROS) Stock Price

KROSStock

$10.66−22.42%52W

Market Cap$211.36M

P/E2.43x

PEG Ratio—

Div yield—

Beta1.20

KROS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.61%

Price vs S&P 500 (4W)-5.82%

VGM Score48.08

P/E Ratio (Annual)2.43x

P/CF (Annual)1.97x

Book Value / Share (Quarterly)$13.23

P/TBV (Annual)3.32x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-43.89%

Cash Flow / Share (Quarterly)$-2.45

Price vs S&P 500 (YTD)-59.57%

Net Profit Margin (TTM)-256.60%

EPS (TTM)$-3.70

10-Day Avg Trading Volume0.17M

EPS Excl Extra (TTM)$-3.70

Revenue Growth (5Y)-18.71%

EPS (Annual)$2.30

ROI (Annual)28.70%

Net Profit Margin (5Y Avg)-21395.35%

Cash / Share (Quarterly)$12.99

P/E Basic Excl Extra (TTM)2.55x

Revenue Growth QoQ (YoY)-99.83%

P/E Normalized (Annual)2.43x

ROA (Last FY)25.74%

Revenue Growth TTM (YoY)-93.55%

EBITD / Share (TTM)$-3.73

ROE (5Y Avg)-22.40%

Operating Margin (TTM)-332.55%

Cash Flow / Share (Annual)$5.42

P/B Ratio0.81x

P/B Ratio (Quarterly)0.81x

Net Income / Employee (Annual)$1,115,600

EV / Revenue (TTM)-1.39x

Net Interest Coverage (TTM)-4552.00x

ROA (TTM)-19.79%

EV / EBITDA (TTM)-0.67x

EPS Incl Extra (Annual)$2.30

Current Ratio (Annual)15.45x

Quick Ratio (Quarterly)21.53x

3-Month Avg Trading Volume0.22M

52-Week Price Return-22.42%

EV / Free Cash Flow (Annual)-0.44x

P/E Incl Extra (TTM)2.55x

Revenue / Employee (TTM)$192,500

Tangible BV / Share (Quarterly)$9.97

P/S Ratio (Annual)0.87x

Asset Turnover (Annual)0.72x

52-Week High$22.55

Operating Margin (5Y Avg)-23768.21%

EPS Excl Extra (Annual)$2.30

CapEx CAGR (5Y)39.84%

26-Week Price Return-7.71%

Quick Ratio (Annual)15.22x

13-Week Price Return0.19%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.96x

Enterprise Value$-46.25M

Revenue / Share Growth (5Y)-28.88%

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)6.58%

Revenue / Employee (Annual)$3,129,000

Pretax Margin (Annual)37.65%

Cash / Share (Annual)$14.71

3-Month Return Std Dev44.95%

Net Income / Employee (TTM)$-1,066,100

ROE (Last FY)28.70%

Net Interest Coverage (Annual)-114790.00x

EPS Basic Excl Extra (Annual)$2.30

Receivables Turnover (TTM)1.90x

EV / Free Cash Flow (TTM)-0.62x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.70

Receivables Turnover (Annual)77.37x

ROI (TTM)-21.40%

P/S Ratio (TTM)6.37x

Pretax Margin (5Y Avg)-21391.26%

Revenue / Share (Annual)$6.45

Tangible BV / Share (Annual)$10.07

Forward P/E6.37x

Price vs S&P 500 (52W)-37.95%

P/E Ratio (TTM)2.55x

Year-to-Date Return-47.64%

5-Day Price Return-8.18%

EPS Normalized (Annual)$2.30

ROA (5Y Avg)-20.63%

Net Profit Margin (Annual)35.65%

Month-to-Date Return-6.49%

Cash Flow / Share (TTM)$-4.93

EBITD / Share (Annual)$1.82

Operating Margin (Annual)27.69%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)2.07x

ROI (5Y Avg)-22.40%

P/E Excl Extra (TTM)2.55x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.70

P/TBV (Quarterly)3.12x

P/B Ratio (Annual)2.05x

Pretax Margin (TTM)-272.15%

Book Value / Share (Annual)$15.51

Price vs S&P 500 (13W)-2.50%

Beta1.20x

P/FCF (Annual)1.99x

Revenue / Share (TTM)$0.76

ROE (TTM)-21.40%

52-Week Low$9.69

vGradeB

gGradeF

mGradeB

vgmGradeC

KROS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$1.24	-$1.45	-16.75%(-$0.21)
Q1 2026	May 14, 2026	-$0.92	-$1.21	-31.52%(-$0.29)
Q4 2025	Mar 4, 2026	-$0.45	-$0.86	-90.40%(-$0.41)
Q3 2025	Nov 5, 2025	-$0.92	-$0.18	+80.46%(+$0.74)
Q2 2025	Aug 6, 2025	-$1.13	-$0.76	+32.54%(+$0.37)

KROS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.86

3.92

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KROSKeros Therapeutics, Inc. Common Stock	B	F	B	6.4x	-93.5%	—	—	$10.66
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Keros Therapeutics, Inc. Common Stock

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel protein therapeutics for blood disorders with significant unmet needs. The company's lead program, KER-050, targets cytopenias—including anemia and thrombocytopenia—in patients with myelodysplastic syndromes and myelofibrosis.

KROS Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.86

Revenue estimate$13.89M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

KROS Insider Transactions

SellAug 18, 2026
CHO ESTHER
Officer
Shares: 4,485Value: $46,151
SellAug 18, 2026
LERNER LORENA RAQUEL PH.D.
Officer
Shares: 3,568Value: $36,715
SellAug 18, 2026
NEWTON CHARLES W.
Director
Shares: 551Value: $5,675
BuyAug 17, 2026
BIENAIME JEAN-JACQUES
Director
Shares: 1,000Value: $10,270

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

IKTInhibikase Therapeutics, Inc. Common StockBiological Products
SABSSAB Biotherapeutics, Inc. Common StockBiological Products
LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.9

Buy

Consensus rating

52-Week Range

Low$9.69

High$22.55